These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 16704637)

  • 1. Sentinel lymph node status in melanoma: a valuable prognostic factor?
    Topar G; Eisendle K; Zelger B; Fritsch P
    Br J Dermatol; 2006 Jun; 154(6):1080-7. PubMed ID: 16704637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.
    Debarbieux S; Duru G; Dalle S; Béatrix O; Balme B; Thomas L
    Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.
    Berk DR; Johnson DL; Uzieblo A; Kiernan M; Swetter SM
    Arch Dermatol; 2005 Aug; 141(8):1016-22. PubMed ID: 16103331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
    Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
    J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
    Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
    Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sentinel lymph node dissection in patients with malignant melanoma. Diagnostic and therapeutic standards].
    Arens A; Osinga J; Schwipper V; Schober O; Tilkorn H; Liebau J
    Chirurg; 2003 Jul; 74(7):665-70. PubMed ID: 12883795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.
    Vaquerano J; Kraybill WG; Driscoll DL; Cheney R; Kane JM
    Ann Surg Oncol; 2006 Feb; 13(2):198-204. PubMed ID: 16418885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
    Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
    Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma of the ear: prognostic factors and surgical strategies.
    Jahn V; Breuninger H; Garbe C; Moehrle M
    Br J Dermatol; 2006 Feb; 154(2):310-8. PubMed ID: 16433802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma.
    Gannon CJ; Rousseau DL; Ross MI; Johnson MM; Lee JE; Mansfield PF; Cormier JN; Prieto VG; Gershenwald JE
    Cancer; 2006 Dec; 107(11):2647-52. PubMed ID: 17063497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?
    Gajdos C; Griffith KA; Wong SL; Johnson TM; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
    Cancer; 2009 Dec; 115(24):5752-60. PubMed ID: 19827151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas.
    Gutzmer R; Satzger I; Thoms KM; Völker B; Mitteldorf C; Kapp A; Bertsch HP; Kretschmer L
    J Dtsch Dermatol Ges; 2008 Mar; 6(3):198-203. PubMed ID: 18093216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
    Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
    J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma.
    Weinlich G; Topar G; Eisendle K; Fritsch PO; Zelger B
    J Eur Acad Dermatol Venereol; 2007 May; 21(5):669-77. PubMed ID: 17447982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Feasibility and technical problems of sentinel node analysis in melanoma].
    Mebazaa A; Kerob D; Toubert ME; Verola O; Servant JM; Baccard M; Billotey C; Bustamante K; Vandici FO; Basset-Seguin N; Ollivaud L; Morel P; Lebbé C
    Ann Chir Plast Esthet; 2007 Feb; 52(1):14-23. PubMed ID: 17141391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tumour regression is not predictive for higher risk of sentinel node involvement in thin melanomas (Breslow thickness < or = 1 mm)].
    Kramkimel N; Maubec E; Boitier F; Cavalcanti A; Beldi M; Mamelle G; Kolb F; Duvillard P; Avril MF
    Ann Dermatol Venereol; 2010 Apr; 137(4):276-80. PubMed ID: 20417360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.